新陈代谢相关的各种合作契约：契约条件・合意内容

本报告，调查分析2007年以后新陈代谢相关的各种合作契约，汇整各种契约的近年动向、大型契约及大型医药品业者的契约概要、契约区分・开发阶段・技术区分・适应症区分别的指南等，由下列摘要形式阐述。

报告摘要

第1章 简介

第2章 新陈代谢相关的各种契约动向

• 简介
• 过去数年新陈代谢相关的合作
• 大型药厂的契约活动
• 对新陈代谢相关事业不积极的大型药厂
• 新陈代谢相关的合作：契约类型别
• 新陈代谢相关的合作：产业部门别
• 新陈代谢相关的合作：开发阶段别
• 新陈代谢相关的合作：技术类型别
• 平均契约期间

第3章 主要契约

• 简介
• 主要契约：交易额别
• 大型药厂涉及的主要契约

第4章 大型药厂的契约

• 简介
• 大型药厂的合作契约利用法
• 企业档案资料

第5章 契约指南

• 简介
• 契约类型别
  • 资产购买
  • 让渡
  • 大型企业的委外授权
  • 共同开发
  • 共同R&D
  • 共同销售
  • 服务契约
  • 共同推广
  • CRADA
  • 交叉授权
  • 开发
  • 销售
  • 股票收购
  • 授权
  • 诉讼
  • 贷款
  • 制造
  • 市场行销
  • 材料移转
  • 选项
  • 促销
  • 研究
  • 权利金融资
  • 合解相关
  • 资产分割
  • 再授权
  • 供给
  • 技术转移
  • 终了
• 开发阶段别
  • 药物设计
  • 制剂
  • 第I阶段
  • 第II阶段
  • 第III阶段
  • 前临床
  • 法规
  • 制剂
• 技术类型别
  • 解析
  • 动物模型
  • 分析
  • 生物学化合物
  • 生物标记
  • 生物材料
  • 血液制剂
  • 细胞培养
  • 细胞治疗
  • 临床检查
  • 装置
  • 诊断
  • 药物设计工具
  • DNA探针
  • 药物传递
  • 促成技术
  • 设备
  • 基因治疗
  • 基因体学
  • 造影
  • 移植
  • 体外模型
  • 微阵列
  • 奈米科技
  • 天然产品
  • 寡核甘酸
  • 孤儿药
  • 包装
  • 胜肽
  • 加工
  • 蛋白质体学
  • 放射性/化学治疗
  • 重组DNA
  • 再生医疗
  • 研究服务
  • 研究提供
  • RNA治疗
  • 筛检
  • 小分子
  • 干细胞
  • 毒性
  • 疫苗

第6章　新陈代谢相关的契约：适应症别

• 新陈代谢
• 肢端肥大症
• 爱迪生病
• 肝硬化
• 库欣氏症候群
• 糖尿病
• 脂肪肝
• 胆石
• 生长激素疾病
• 甲状腺机能亢进症
• 性腺低能症
• 甲状腺功能减退症
• 苯酮尿症
• 肝病
• 溶小体糖脂类储积症
• 营养素・维他命
• 身材矮小症
• 抗利尿素分泌异常症(SIADH)
• 甲状腺疾病

第6章 合作机会

• 线上伙伴
• 伙伴活动
• 相关资料

附录

图表

Global Metabolic Partnering 2014-2020: Deal trends, players and financials report provides comprehensive understanding and unprecedented access to the metabolic partnering deals and agreements entered into by the worlds leading healthcare companies

Global Metabolic Partnering 2014 to 2020 provides the full collection of Metabolic disease deals signed between the world's pharmaceutical and biotechnology companies since 2014.

Trends in Metabolic partnering deals

Financial deal terms for headline, upfront and royalty by stage of development

Metabolic partnering agreement structure

Metabolic partnering contract documents

Top Metabolic deals by value

Most active Metabolic dealmakers

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Metabolic disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Metabolic deals.

The report presents financial deal terms values for Metabolic deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Metabolic dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Metabolic dealmaking since 2014 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Metabolic deals since 2014. Deals are listed by headline value. The chapter includes the top 25 most active Metabolic dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Metabolic deals since 2014 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Metabolic partnering deals by specific Metabolic target announced since 2014. The chapter is organized by specific Metabolic therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Metabolic partnering deals signed and announced since 2014. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Metabolic partnering and dealmaking since 2014.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Metabolic technologies and products.

Report scope

Global Metabolic Partnering 2014 to 2020 is intended to provide the reader with an in-depth understanding and access to Metabolic trends and structure of deals entered into by leading companies worldwide.

Global Metabolic Partnering 2014 to 2020 includes:

• Trends in Metabolic dealmaking in the biopharma industry since 2014
• Analysis of Metabolic deal structure
• Access to headline, upfront, milestone and royalty data
• Access to hundreds of Metabolic deal contract documents
• Comprehensive access to over 1000 Metabolic deal records
• The leading Metabolic deals by value since 2014
• Most active Metabolic dealmakers since 2014
• The report includes deals for the following indications: Acromegaly, Addison's disease, Cirrhosis, Cushing's syndrome, Diabetes, Type 1, Type 2, Insipidus, Fatty liver, Gallstones, Goitre, Growth hormone disorders, Gynaecomastia, Inborn errors of metabolism, Phenylketonuria, Hyperaldosteronism, Hypercalcaemia, Hyperthyroidism, Hypocalcaemia, Hypogonadism, Hypopituitarism, Hypothyroidism, Liver disease, Nonalcoholic steatohepatitis (NASH), Lysosomal storage disorders, Nutrition and vitamins, Rickets, Pheochromocytoma, Primary bilary cirrhosis, Prolactinemia, Short stature, Syndrome of Inappropriate Antidiuretic Hormone (SIADH), Thyroid disease, plus other metabolic indications.

In Global Metabolic Partnering 2014 to 2020, available deals and contracts are listed by:

• Headline value
• Upfront payment value
• Royalty rate value
• Stage of development at signing
• Deal component type
• Technology type
• Specific therapy indication
• Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Metabolic Partnering 2014-2020 report provides comprehensive access to available deals and contract documents for over 1000 metabolic deals. Analyzing actual contract agreements allows assessment of the following:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are the sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Benefits

Global Metabolic Partnering 2014 to 2020 provides the reader with the following key benefits:

• In-depth understanding of Metabolic deal trends since 2014
• Access Metabolic deal headline, upfront, milestone and royalty data
• Research hundreds of actual contracts between Metabolic partner companies
• Comprehensive access to over 1000 links to actual Metabolic deals entered into by the world's biopharma companies
• Indepth review of Metabolic deals entered into by the top 25 most active dealmakers
• Benchmark the key deal terms companies have agreed in previous deals
• Identify key terms under which companies partner Metabolic opportunities
• Uncover companies actively partnering Metabolic opportunities

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Metabolic dealmaking

• 2.1. Introduction
• 2.2. Metabolic partnering over the years
• 2.3. Metabolic partnering by deal type
• 2.4. Metabolic partnering by industry sector
• 2.5. Metabolic partnering by stage of development
• 2.6. Metabolic partnering by technology type
• 2.7. Metabolic partnering by therapeutic indication

Chapter 3 -Financial deal terms for Metabolic partnering

• 3.1. Introduction
• 3.2. Disclosed financials terms for Metabolic partnering
• 3.3. Metabolic partnering headline values
• 3.4. Metabolic deal upfront payments
• 3.5. Metabolic deal milestone payments
• 3.6. Metabolic royalty rates

Chapter 4 - Leading Metabolic deals and dealmakers

• 4.1. Introduction
• 4.2. Most active in Metabolic partnering
• 4.3. List of most active dealmakers in Metabolic
• 4.4. Top Metabolic deals by value

Chapter 5 - Metabolic contract document directory

• 5.1. Introduction
• 5.2. Metabolic partnering deals where contract document available

Chapter 6 - Metabolic dealmaking by therapeutic target

• 6.1. Introduction
• 6.2. Deals by Metabolic therapeutic target

Appendices

• Appendix 1 - Directory of Metabolic deals by company A-Z since 2014
• Appendix 2 - Directory of Metabolic deals by deal type since 2014
• Appendix 3 - Directory of Metabolic deals by stage of development since 2014
• Appendix 4 - Directory of Metabolic deals by technology type since 2014
• Further reading on dealmaking
• Deal type definitions
• About Wildwood Ventures
• Current Partnering
• Current Agreements
• Recent report titles from CurrentPartnering
• Table of figures
• Figure 1: Metabolic partnering since 2014
• Figure 2: Metabolic partnering by deal type since 2014
• Figure 3: Metabolic partnering by industry sector since 2014
• Figure 4: Metabolic partnering by stage of development since 2014
• Figure 5: Metabolic partnering by technology type since 2014
• Figure 6: Metabolic partnering by indication since 2014
• Figure 7: Metabolic deals with a headline value
• Figure 8: Metabolic deals with upfront payment values
• Figure 9: Metabolic deals with milestone payment
• Figure 10: Metabolic deals with royalty rates
• Figure 11: Active Metabolic dealmaking activity sinc 2014
• Figure 12: Top Metabolic deals by value since 2014